ALPHA-LIPOE VA ACID: POLYFACTOR INFLUENCE AND RATIONALE OF OPPORTUNITIES FOR USE IN SUGAR DIABETES

Authors

  • Mohort T. V. Belarusian State Medical University, Minsk, Belarus

DOI:

https://doi.org/10.21856/j-PEP.2017.4.07

Keywords:

diabetes mellitus, α-lipoic acid

Abstract

The article has scientific data overview of the lipoic acid positive impact on diabetes complications.
The mechanism of action and clinical relevance of lipoic acid in patients with carbohydrate metabolism impairment is described. The different studies of lipoic acid efficacy in symptoms treatment (pain, burning, parenthesis, numbness) as well as eliminating the neuropathic deficiency in patients with diabetic neuropathy are presented. Defined the significant role for preventing trophic complications in diabetes mellitus. Additional effects of lipoic acid were shown.

References

Packer L, Witt EH, Tritschler H. Free Radic Biol Med 1995; 19:227-250.

Reed LJ. Acc Chem Res 1974; 7: 40-46.

Dincer Y, Telci A, Kayali R, et al. Clin Exp Pharmacol Physiol 2002; 29: 281-284.

Smith AR, Shenvi SV, Widlansky M, et al. Curr Med Chem 2004; 11(9): 1135-1146.

Padmalayam I, Hasham S, Saxena U, Pillarisetti S. Diabetes 2009; 58(3): 600-608.

Midaoui AE, Elimadi A, Wu L, et al. Am J Hypertens 2003; 16(3): 173-179.

Nagamatsu M, Nickander KK, Schmelzer JD, et al. Diabetes Care 1995; 18: 1160-1167.

Stevens MJ, Obrosova I, Cao X, et al. Diabetes 2000; 49: 1006-1015.

Sytze V. Diabetes Metab Res Rev 2002; 18: 176-184.

Ziegler D. Treat Endocrinol 2004; 3: 173-189.

Ametov AS, Barinov A, Dyck PJ, et al. Diabetes Care 2003; 26: 770-776.

Ziegler D, Ametov A, Barinov A, et al. Diabetes Care 2006; 29: 2365-2370.

Ziegler D, Schatz H, Conrad F, et al. Diabetes Care 1997; 20: 369-373.

Holmquist L, Stuchbury G, Berbaum K. Pharmacol Ther 2007; 113(1): 154-164.

Maczurek A, Hager K, Kenklies M, et al. Adv Drug Deliv Rev 2008; 60(13-14): 1463-1470.

Melhem MF, Craven PA, Derubertis FR. J Am Soc Nephrol 2001; 12(1): 124-133.

Melhem MF, Craven PA, Liachenko J, et al. J Am Soc Nephrol 2002; 13: 108-116.

Mervaala E, Finckenberg P, Lapatto R, et al. Kidney Int 2003; 64(2): 501-508.

Morcos M, Borcea V, Isermann B, et al. Diabetes Res Clin Pract 2001; 52(3): 175-183.

Teichert J, Tuemmers T, Achenbach H, et al. J Clin Pharmacol 2005; 45(3): 313-328.

Kowlulu RA, Odenbach S. Diabetes 2004; 53(12): 3233-3238.

Lin J, Bierhaus A, Bugert P, et al. Diabetologia 2006; 49: 1089-1096.

Borenshtein D, Ofri R, Werman M, et al. Diabetes Metab Res Rev 2001; 17: 44-50.

Packer L, Kraemer K, Rimbach G. Nutrition 2001; 17(10): 888-895.

Keegan A, Cotter MA, Cameron NE. Diabetes Metab Res Rev 2001; 17(5): 380-386.

Midaui AE, de Champlain J. Hypertension 2002; 39(2): 303-307.

Koçak G, Aktan F, Canbolat O, et al. Diabetes Nutr Metab 2000; 13(6): 308-318.

Ghibu S, Richard C, Vergely C, et al. J Cardiovasc Pharmacol 2009; 54(5): 391-398.

Sola S, Mir MQ, Cheema FA, et al. Circulation 2005; 111: 343-348.

Bustamante J, Lodge JK, Marcocci L, et al. Free Radic Biol Med 1998; 24(6): 1023-1039.

Eason RC, Archer HE, Akhtar S, Bailey СJ. Diabetes Obes Metab 2002; 4: 29-35.

Park KG, Min AK, Koh EH, et al. Hepatology 2008; 48(5): 1477-1486.

Ramrath S, Tritchler HJ, Eckel J. Horm Metab Res 1999; 31: 632-635.

Jacob S, Rett K, Henriksen EJ, et al. Biofactors 1999; 10:169-174.

Kamenova P. Hormones (Athens) 2006;5: 251-258.

Konrad T, Vicini P, Kusterer K, et al. Diabetes Care 1999; 22: 280-287.

Konrad D. Antioxid Redox Signal 2005;7: 1032-1039.

Yaworsky K, Somwar R, Ramlal T, et al. Diabetologia 2000; 43: 294-303.

Singh U, Jialal I. Nutr Rev 2008;66(11): 646-657.

Ruhe RC, McDonald RB. J Am Coll Nutr 2001; 20: 363S-369S.

Downloads

Published

2017-10-30

How to Cite

Мохорт, Т. В. (2017). ALPHA-LIPOE VA ACID: POLYFACTOR INFLUENCE AND RATIONALE OF OPPORTUNITIES FOR USE IN SUGAR DIABETES. Problems of Endocrine Pathology, 62(4), 55-63. https://doi.org/10.21856/j-PEP.2017.4.07